Biodesix Q2 2026 revenue $26.9M (+34% YoY); net loss improves 37% to $7.3M

BIODESIX INC

Diagnostic testing revenue $25.4M (+42% YoY) on 20,900 test volumes (+38%).
Gross margin 82% (up 200 bps); operating expenses +7% vs revenue +34% shows leverage.
Net loss $7.3M (improved 37%); Adjusted EBITDA loss $3.2M (improved 56%).
FY 2026 revenue guidance maintained at $108-114M (midpoint ~25% growth); gross margin ~80%.
Cash $30.0M, up 17% from Q1 2026; includes $6.5M from ATM program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.